Ciloa SAS
Created in 2011
Up & running (A)
Existing signals show a regular activitySocial networks
1,410Activities
Technologies
Entity types
Location
356 Rue Maurice Béjart, 34080 Montpellier, France
Montpellier
France
Employees
Scale: 11-50
Estimated: 12
Engaged corporates
4
3 0Added in Motherbase
2 years, 1 month ago
biotech Value proposition
Inspired by Exosomes
CILOA’S CUSTOMIZED EXOSOMES FOR INNOVATIVE THERAPEUTICS
Ciloa is the most experienced exosome-based R&D Company dedicated to the development of new high-potential bio-drugs. By overcoming undruggable targets, Ciloa supports your projects to create new therapeutic and new preventive solutions.
Ciloa customizes in vivo exosomes to contain i) fully native membrane protein complexes (GPCRs, Kinase Receptors, Ion Channels, Viral Antigens, Transporters...) embedded in their membrane and ii) chosen cargo proteins inside their cytosol.
Natural properties of exosomes combined with Ciloa in vivo disruptive technology allow to develop:
- VIRUS-FREE candidate THERAPEUTIC VECTORS able to deliver specifically chosen cargos to any diseased organ.
- ANTIBODIES AGAINST UNDRUGGABLE MEMBRANE PROTEIN COMPLEX TARGETS by unlocking all bottlenecks of the antibody development process.
- ADJUVANT & VIRUS-FREE candidate VACCINES, thanks to the combination of perfect antigens with the potent natural adjuvant properties of exosomes.
Ciloa works through Licensing and Partnerships.
Screening ligand binding to membrane receptors, Development of native transmembrane proteins, Development of therapeutic antibodies, Development of vaccines, Development of therapeutic vectors, Pioneer of exosome based therapies and vaccines, and Exosome purification and productionOriginal language
Inspired by Exosomes
CILOA’S CUSTOMIZED EXOSOMES FOR INNOVATIVE THERAPEUTICS
Ciloa is the most experienced exosome-based R&D Company dedicated to the development of new high-potential bio-drugs. By overcoming undruggable targets, Ciloa supports your projects to create new therapeutic and new preventive solutions.
Ciloa customizes in vivo exosomes to contain i) fully native membrane protein complexes (GPCRs, Kinase Receptors, Ion Channels, Viral Antigens, Transporters...) embedded in their membrane and ii) chosen cargo proteins inside their cytosol.
Natural properties of exosomes combined with Ciloa in vivo disruptive technology allow to develop:
- VIRUS-FREE candidate THERAPEUTIC VECTORS able to deliver specifically chosen cargos to any diseased organ.
- ANTIBODIES AGAINST UNDRUGGABLE MEMBRANE PROTEIN COMPLEX TARGETS by unlocking all bottlenecks of the antibody development process.
- ADJUVANT & VIRUS-FREE candidate VACCINES, thanks to the combination of perfect antigens with the potent natural adjuvant properties of exosomes.
Ciloa works through Licensing and Partnerships.
Ciloa, Inspired by exosomes
Ciloa is dedicated to the development of new high potential therapies. It was built on more than 15 years of research. Our technology produce all types of membrane proteins with their native conformation on exosomes. It makes possible to reach the most difficult families of membrane protein targets,
https://www.ciloa.fr/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 | SATT AxLR | Other 7 Mar 2025 | | |
 Créalia Occitanie Civic and Social Organizations | Créalia Occitanie Civic and Social Organizations | Other 15 Mar 2024 | | |
 French Tech Méditerranée French Tech, Software Development | French Tech Méditerranée French Tech, Software Development | Other 14 Mar 2024 | | |
 Eurobiomed Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Eurobiomed Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 7 Jul 2023 | | |